Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial

 
• By Jessica Merrill
  
Comparison scale
Pfizer says abrocitinib performed better than Dupixent in a Phase III trial • Source: Alamy

More from Immunological

More from Therapy Areas